Ella Hohmann, MS

Hans Lee, MD, lays out the tradeoffs in travel, time off therapy, and who each option realistically fits when looking at CAR T-cell and bispecific therapies.

Panel experts at Nashville’s IVBM event discussed matching cancer therapy intensity to disease, easing access barriers, and reforming pharmacy/PBM policies.

Denise Yardley, MD, on OPTIMA, Prosigna proliferation scoring, and telling patients an endocrine strategy fits how their tumor behaves.

Vicki Keedy, MD, speaks to sarcoma research funding gaps, delayed diagnosis, and why the European specialty center model outperforms US referral patterns.

Integrated specialty pharmacies have EHR access, faster prior authorizations, and built-in monitoring, Brooke Looney, PharmD, CSP, highlighted.

Benjamin Garmezy, MD, explains what varying Nectin-4 expression means for treatment selection in bladder cancer and what trials are still needed.

Clinical trial access remains the biggest barrier in sarcoma care, with travel and insurance limits keeping patients from open studies, says Vicki Keedy, MD.

Justin Balko, PharmD, PhD, explains why residual disease in triple-negative breast cancer signals a biology gap, and what ADC trials and cell-free DNA monitoring may reveal.

Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, BCOP, and bispecifics will bring another shift.

Women with PMOS had more than 4 times the adjusted ASCVD risk of matched peers, and traditional risk factors explained only about a third of the gap.

AI-guided breast screening is advancing faster than coverage policy, guidelines, and imaging capacity—raising questions about who qualifies and who pays.

GLP-1 use in adolescents and young adults with obesity rose to 96.1% as bariatric surgery fell by two-thirds, new JAMA Pediatrics data show.

SNAP participation was linked to a smaller colorectal cancer screening gap among food-insecure US adults, ananalysis of 251,000 found.

Alexander Spira, MD, PhD, FACP, FASCO, explains why sarcoma treatment lags behind other solid tumors and the access, subtype, and biomarker barriers.

FDA clears perioperative Keytruda + Padcev for all patients with muscle-invasive bladder cancer, establishing a new cisplatin-independent standard of care.

6 leading AI chatbots scored below 28% on a colorectal cancer knowledge test when barred from reasoning, raising fresh safety concerns for clinical use.

The first half of 2026 saw the FDA approve 5 notable first-in-class therapies across obesity, AML, kidney disease, hearing loss, and bladder cancer.

Quest Diagnostics is integrating its Haystack MRD and genomic profiling tests into Flatiron's OncoEMR, starting with an AON community oncology pilot.

Vera's atacicept (Trutakna) wins FDA accelerated approval after a 46% proteinuria drop in the ORIGIN 3 trial.

A proposed 2027 CMS rule would cut 340B Drug Pricing Program payments to curb Medicare drug costs and shift savings to patients.

Sarcoma's rarity and molecular diversity complicate trial design. Alexander Spira, MD, PhD, FACP, FASCO discusses biomarker testing, NGS panels, and referral gaps.

OLC's second complete response letter reflects an unresolved third-party manufacturing inspection, not new efficacy or safety concerns from the FDA.

Breast density raises cancer risk and masks tumors on mammography. Danielle Holt, MD, MSS, explains why density alone shouldn't trigger more imaging.

The FDA approved sacituzumab govitecan-hziy alone or with pembrolizumab as first-line therapy for metastatic triple-negative breast cancer.

Boston specialists discussed CKM syndrome, UACR screening gaps, and GDMT sequencing at a population health roundtable.

Caregivers of patients with CKD report social withdrawal, strained relationships, and stigma, according to a new qualitative evidence synthesis.

FDA approves palbociclib (Ibrance) for HR+, HER2+ metastatic breast cancer maintenance, based on phase 3 PATINA data showing a 24% reduction in progression risk.

FDA approval of generic rifapentine introduces a new option for treating active tuberculosis and preventing progression of latent infection.

EXTEND trial data show nurse-delivered telehealth for type 2 diabetes missed its primary end point in fee-for-service care, raising questions about reimbursement.

Alexander Spira, MD, PhD, FACP, FASCO, on why sarcoma diagnosis is often delayed and how community-academic collaboration speeds treatment.